Kyongbo Pharmaceutical Co., Ltd (214390.KS)

Kyongbo Pharmaceutical Co., Ltd (214390.KS) — VMCI valuation read

Across 120 indicators, Kyongbo Pharmaceutical Co., Ltd (214390.KS) lands at VMCI 37/100. The Healthcare sector median is 50, so the 13-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 214390.KS in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 214390.KS trades at 23.0x earnings, 28% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 0.2x leaves covenant headroom for 214390.KS on the trailing balance sheet.

214390.KS rose 3.4% over the trailing 7 days, with a -23.5% read on a 30-day basis.